FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma Patients – PR Newswire (press release)
|
FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin's Lymphoma Patients
PR Newswire (press release) Yescarta is a Chimeric Antigen Receptor (CAR) T cell therapy, also known as CAR-T. Moffitt Cancer Center's Frederick Locke, M.D., is the co-lead investigator of the pivotal ZUMA-1 clinical trial that tested the new therapy, which is manufactured by … FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma |
